KR102663430B1 - Composition for improving hair loss containing personalized dermal papilla cell culture medium - Google Patents
Composition for improving hair loss containing personalized dermal papilla cell culture medium Download PDFInfo
- Publication number
- KR102663430B1 KR102663430B1 KR1020210109018A KR20210109018A KR102663430B1 KR 102663430 B1 KR102663430 B1 KR 102663430B1 KR 1020210109018 A KR1020210109018 A KR 1020210109018A KR 20210109018 A KR20210109018 A KR 20210109018A KR 102663430 B1 KR102663430 B1 KR 102663430B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- weight
- cell culture
- hair loss
- dermal papilla
- Prior art date
Links
- 230000002500 effect on skin Effects 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 26
- 208000024963 hair loss Diseases 0.000 title claims abstract description 24
- 230000003752 improving hair Effects 0.000 title claims abstract description 18
- 239000006143 cell culture medium Substances 0.000 title claims description 18
- 238000004113 cell culture Methods 0.000 claims abstract description 11
- 239000003102 growth factor Substances 0.000 claims abstract description 10
- 229940079868 disodium laureth sulfosuccinate Drugs 0.000 claims description 8
- YGAXLGGEEQLLKV-UHFFFAOYSA-L disodium;4-dodecoxy-4-oxo-2-sulfonatobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)CC(C([O-])=O)S([O-])(=O)=O YGAXLGGEEQLLKV-UHFFFAOYSA-L 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 8
- 239000002453 shampoo Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 claims description 4
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims description 4
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 4
- 244000246386 Mentha pulegium Species 0.000 claims description 4
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 4
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 4
- 240000007817 Olea europaea Species 0.000 claims description 4
- 235000004347 Perilla Nutrition 0.000 claims description 4
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 235000001050 hortel pimenta Nutrition 0.000 claims description 4
- 102000057239 human FGF7 Human genes 0.000 claims description 4
- 102000058223 human VEGFA Human genes 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 241000195940 Bryophyta Species 0.000 claims description 3
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 102000057308 human HGF Human genes 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000003595 mist Substances 0.000 claims description 3
- 235000011929 mousse Nutrition 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000001256 tonic effect Effects 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 239000012930 cell culture fluid Substances 0.000 claims description 2
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 claims 1
- 244000124853 Perilla frutescens Species 0.000 claims 1
- 230000003796 beauty Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 28
- 210000004209 hair Anatomy 0.000 description 27
- 239000002609 medium Substances 0.000 description 17
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 210000003780 hair follicle Anatomy 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000003721 exogen phase Effects 0.000 description 4
- 230000003779 hair growth Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000229722 Perilla <angiosperm> Species 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 229960003942 amphotericin b Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 210000004186 follicle cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 모유두세포배양액을 함유한 탈모개선용 조성물에 관한 발명으로, 더욱 상세하게는 탈모방지 및 개선에 효과적인 성장인자(Growth Factor)가 다수 함유되어 있는 모유두세포배약액을 함유한 탈모개선용 조성물에 관한 발명으로, 본 발명에 의한 조성물은 탈모개선에 중요한 역할을 할 수 있는 점에서, 본 발명은 의료분야, 미용분야 등 다양한 산업분야에서 활용이 가능하다. The present invention relates to a composition for improving hair loss containing a dermal papilla cell culture solution, and more specifically, to a composition for improving hair loss containing a dermal papilla cell culture solution containing a large number of growth factors effective in preventing and improving hair loss. Since the composition according to the present invention can play an important role in improving hair loss, the present invention can be used in various industrial fields such as the medical field and the beauty field.
Description
본 발명은 모유두세포배양액을 함유한 탈모개선용 조성물에 관한 발명으로, 더욱 상세하게는 탈모방지 및 개선에 효과적인 성장인자(Growth Factor)가 다수 함유되어 있는 모유두세포배약액을 함유한 탈모개선용 조성물에 관한 발명이다. The present invention relates to a composition for improving hair loss containing a dermal papilla cell culture solution, and more specifically, to a composition for improving hair loss containing a dermal papilla cell culture solution containing a large number of growth factors effective in preventing and improving hair loss. It is an invention about.
탈모증(alopecia)은 질병, 영양부족, 노화, 호르몬 불균형 등에 의해 야기되는 것으로 알려져 있다. 많은 연구가 진행되어 왔음에도 불구하고, 근본적인 탈모에 대한 메커니즘은 잘 알려져 있지 않으나, 일반적으로 모발은 일정한 모주기(hair cycle)를 거치게 되며, 모유두(dermal papilla)의 자극을 받은 모모세포(keratinocyte)가 활발히 분열·증식하여 모발이 자라는 성장기(anagen), 모구(hair bulb)에 혈액공급이 끊기고 모유두가 모낭으로부터 분리되는 퇴행기(catagen) 및 세포 증식이 멈춰 모발이 성장하지 않는 휴지기(telogen)를 거쳐 다시 성장기로 들어가거나 모발이 두피로부터 빠지는 탈락기(exogen)로 가게 된다. 사람의 모발은 각각 독립된 성장주기를 가져 일부는 탈락기로, 일부는 성장기로 들어가며 전체적으로 동일 수준의 모발수를 유지하게 되는데, 이러한 균형이 탈락기로 기울어 정상적으로 모발이 존재해야 할 부위에 모발이 없어지는 상태를 탈모증(alopecia)이라 한다. Alopecia is known to be caused by disease, malnutrition, aging, hormonal imbalance, etc. Although much research has been conducted, the fundamental mechanism of hair loss is not well known. Generally, hair goes through a certain hair cycle, and keratinocytes stimulated by the dermal papilla It goes through the growth phase (anagen), when the hair actively divides and proliferates and the hair grows, the catagen phase, when the blood supply to the hair bulb is cut off and the dermal papilla separates from the hair follicle, and the resting phase (telogen), when cell proliferation stops and hair does not grow. It either goes into the anagen phase again or into the shedding phase (exogen), when the hair falls out from the scalp. Human hair has an independent growth cycle, with some entering the shedding phase and some entering the growing phase, maintaining the same level of hair overall. However, this balance tilts toward the shedding phase, causing hair to disappear from areas where hair should normally exist. It is called alopecia.
또한 탈모를 치료하기 위한 노력도 진행되어 왔다. 그럼에도 불구하고, 지금까지 오직 두 개의 약물들 (피나스테라이드(finasteride) 및 미녹시딜(minoxidil))만이 탈모 치료를 위해 FDA(Food and Drug Administration) (U.S.A)에서 인가되었다.Efforts have also been made to treat hair loss. Nevertheless, so far only two drugs (finasteride and minoxidil) have been approved by the Food and Drug Administration (FDA) (U.S.A.) for the treatment of hair loss.
인체의 모발은 약 10만∼15만 개 정도이며 모낭(hair follicle)에서 형성된다. 모낭에는 유두가 있는데, 이 부위에는 작은 혈관이 분포되어 모발의 성장에 필요한 영양분을 공급하고 유두 위의 옆으로는 모발에 윤기를 주는 기름을 공급해주는 지루샘이 있다. 모낭은 여러 다른 상피세포들(epithelial cells) 및 모유두세포들로 이루어진다. 모유두세포는 모낭의 기저부에 위치한 중간엽-유래 섬유아세포(mesenchymally-derived fibroblasts)이며 육모에 중요한 역할을 한다. 특히, 미녹시딜(minoxidil)은 모유두세포의 증식 및 항-세포사멸 효과를 가지는 것으로 보고되었다. 그러나, 이러한 모유두세포의 배양액을 이용하여 탈모개선용 조성물을 제공하는 발명은 기존에 존재하지 않았다. There are approximately 100,000 to 150,000 hairs in the human body, and they are formed in hair follicles. There is a papilla in the hair follicle, and small blood vessels are distributed in this area to supply nutrients necessary for hair growth. Next to the papilla, there is a seborrheic gland that supplies oil that gives hair shine. Hair follicles are made up of several different epithelial cells and dermal papilla cells. Dermal papilla cells are mesenchymally-derived fibroblasts located at the base of hair follicles and play an important role in hair growth. In particular, minoxidil has been reported to have proliferation and anti-apoptotic effects on dermal papilla cells. However, there has been no existing invention providing a composition for improving hair loss using the culture medium of these dermal papilla cells.
본 발명은 모유두세포배양액을 함유한 탈모개선용 조성물을 제공하고자 한다. The present invention seeks to provide a composition for improving hair loss containing dermal papilla cell culture medium.
상기와 같은 문제를 해결하기 위해 본 발명은 모유두세포배양액을 1중량% 포함하는 탈모개선용 조성물을 제공한다.In order to solve the above problems, the present invention provides a composition for improving hair loss containing 1% by weight of dermal papilla cell culture medium.
본 발명에 있어서, 조성물은 자소엽 추출물 20 중량%, LES(Disodium Laureth Sulfosuccinate) 18 중량%, 코코베타인 14 중량%, 올리브 계면활성제 14 중량%, 글루카메이트 3.2 중량%, 모유두세포 배양액 1 중량%, 유로 나프리 0.6 중량%, 페퍼민트 정유 추출물 0.4 중량%, 로즈마리 정유 추출물 0.4 중량%, 폴리쿼터 0.4 중량% 및 정제수를 포함할 수 있다.In the present invention, the composition contains 20% by weight of perilla leaf extract, 18% by weight of LES (Disodium Laureth Sulfosuccinate), 14% by weight of coco betaine, 14% by weight of olive surfactant, 3.2% by weight of glucamate, and 1% by weight of dermal papilla cell culture medium. %, 0.6% by weight of euronapri, 0.4% by weight of peppermint essential oil extract, 0.4% by weight of rosemary essential oil extract, 0.4% by weight of polyquart, and purified water.
또한 본 발명에 있어서, 조성물은 성장인자(Growth Factor)를 함유할 수 있다. Additionally, in the present invention, the composition may contain growth factors.
또한 본 발명에 있어서, 성장인자는 Human VEGF, Human KGF, Human HGF, Human Fibronectin, Human FGF 및 Human Collagen일 수 있다. Additionally, in the present invention, the growth factor may be Human VEGF, Human KGF, Human HGF, Human Fibronectin, Human FGF, and Human Collagen.
또한, 본 발명에 있어서 조성물은 샴푸, 린스, 컨디셔너, 토닉, 에센스, 세럼, 트리트먼트, 로션, 왁스, 젤, 스프레이, 무스, 미스트, 또는 크림으로 제형화될 수 있다. Additionally, in the present invention, the composition may be formulated as a shampoo, rinse, conditioner, tonic, essence, serum, treatment, lotion, wax, gel, spray, mousse, mist, or cream.
본 발명에 의한 조성물은 탈모개선에 현저한 효과를 나타내는 점에서, 본 발명은 의료분야, 미용분야 등 다양한 산업분야에서 활용이 가능하다. Since the composition according to the present invention has a significant effect on improving hair loss, the present invention can be used in various industrial fields such as the medical field and the beauty field.
도 1은 모구로부터 모유두세포를 분리하는 방법에 따른 세포수득률의 차이를 비교하여 나타낸 것이다.
도 2는 모유두세포 배양액 조성비에 따른 스크래치 에세이(Scratch Assay) 결과를 비교하여 나타낸 것이다.
도 3은 모유두세포 배양액 조성비에 따른 Cell Proliferation Assay 결과를 비교하여 나타낸 것이다.
도 4는 모유두세포 배양액에 함유된 성장인자 확인을 위한 ELISA Assay 결과를 나타낸 것이다.Figure 1 shows a comparison of the difference in cell yield depending on the method of isolating dermal papilla cells from hair bulbs.
Figure 2 shows a comparison of scratch assay results according to the composition ratio of the dermal papilla cell culture medium.
Figure 3 shows a comparison of Cell Proliferation Assay results according to the composition ratio of the dermal papilla cell culture medium.
Figure 4 shows the results of ELISA Assay to confirm growth factors contained in dermal papilla cell culture medium.
본 발명에 의한 일 실시예에서는, 모유두세포배양액을 함유한 탈모개선용 조성물을 제공한다. In one embodiment of the present invention, a composition for improving hair loss containing a dermal papilla cell culture medium is provided.
본 발명에 의한 다른 실시예에서, 조성물은 모유두세포배양액을 1 중량% 포함할 수 있다. In another embodiment according to the present invention, the composition may include 1% by weight of dermal papilla cell culture medium.
본 발명에 의한 또 다른 실시예에서, 조성물은 자소엽 추출물 20 중량%, LES(Disodium Laureth Sulfosuccinate) 18 중량%, 코코베타인 14 중량%, 올리브 계면활성제 14 중량%, 글루카메이트 3.2 중량%, 모유두세포 배양액 1 중량%, 유로 나프리 0.6 중량%, 페퍼민트 정유 추출물 0.4 중량%, 로즈마리 정유 추출물 0.4 중량%, 폴리쿼터 0.4 중량% 및 정제수를 포함할 수 있다. In another embodiment according to the present invention, the composition includes 20% by weight of perilla leaf extract, 18% by weight of LES (Disodium Laureth Sulfosuccinate), 14% by weight of cocobetaine, 14% by weight of olive surfactant, 3.2% by weight of glucamate, It may include 1% by weight of dermal papilla cell culture medium, 0.6% by weight of Euronapri, 0.4% by weight of peppermint essential oil extract, 0.4% by weight of rosemary essential oil extract, 0.4% by weight of polyquart, and purified water.
본 발명에 의한 또 다른 실시예에서, 조성물은 성장인자(Growth Factor)를 함유할 수 있다. In another embodiment of the present invention, the composition may contain growth factors.
본 발명에 의한 또 다른 실시예에서, 성장인자는 Human VEGF, Human KGF, Human HGF, Human Fibronectin, Human FGF 및 Human Collagen일 수 있다. In another embodiment according to the present invention, the growth factors may be Human VEGF, Human KGF, Human HGF, Human Fibronectin, Human FGF, and Human Collagen.
본 발명에 의한 또 다른 실시예에서, 상기 조성물은 샴푸, 린스, 컨디셔너, 토닉, 에센스, 세럼, 트리트먼트, 로션, 왁스, 젤, 스프레이, 무스, 미스트, 또는 크림으로 제형화될 수 있다. In another embodiment of the present invention, the composition may be formulated as a shampoo, rinse, conditioner, tonic, essence, serum, treatment, lotion, wax, gel, spray, mousse, mist, or cream.
이하, 구체적인 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through specific examples. These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as limited by these examples.
실시예 1. 두피조직으로부터 모구의 분리Example 1. Isolation of hair bulbs from scalp tissue
멸균된 90 mm 페트리 디쉬(petri dish)에 MEM alpha 배지를 피험자로부터 채취한 두피 조직(표피에서 진피층까지)이 잠기도록 채운 후, 90 mm 페트리 디쉬(petri dish) 덮개에 MEM alpha 배지를 이용하여 여러 개의 드롭(drop)을 형성시키고, 미세수술용 가위와 포셉(forcep)을 이용하여 진피층의 모구를 하나씩 분리하여 준비한 드롭(drop)으로 옮겼다. 이 후, 드롭(drop)으로 이동된 모구를 실체현미경으로 관찰하며 26G 시린지(syringe)와 미세수술용 포셉을 이용하여 모구 말단에 부착되어 있는 지방조직(fatty tissue) 및 모간(hair shaft) 등을 제거하여 두피조직으로부터 모구를 분리하였다. 본 발명에서 “모구”는 모낭에 의하여 싸여 있는 모근의 하부에 형성되어 있는 두꺼운 곤봉형 구조로서, 모세혈관, 모유두세포, 모모세포 등이 위치하는 조직을 의미한다. After filling a sterilized 90 mm Petri dish with MEM alpha medium to submerge the scalp tissue (from the epidermis to the dermal layer) collected from the subject, several layers were placed on the 90 mm Petri dish cover using MEM alpha medium. A drop was formed, and the hair bulbs in the dermal layer were separated one by one using microsurgical scissors and forceps and transferred to the prepared drop. Afterwards, the hair bulb moved to the drop is observed under a stereomicroscope, and the fatty tissue and hair shaft attached to the end of the hair bulb are removed using a 26G syringe and microsurgical forceps. The hair bulb was separated from the scalp tissue by removal. In the present invention, “hair bulb” is a thick club-shaped structure formed at the lower part of the hair root surrounded by hair follicles, and refers to the tissue in which capillaries, dermal papilla cells, hair hair cells, etc. are located.
실시예 2. 모구로부터 모유두세포의 분리Example 2. Isolation of dermal papilla cells from hair bulbs
모구로부터 모유두세포를 분리하는 최적의 방법을 선택하기 위하여 하기와 같은 비교실험을 하였다. In order to select the optimal method for separating dermal papilla cells from hair bulbs, the following comparative experiment was performed.
먼저, 분리 방법 1은 35 mm 세포배양접시(cell culture dish)에 1 ml 의 분리배지(Dissection media)를 넣고 모구 약 50개를 넣은 후 정밀미세가위로 초핑(chopping)한 후 튜브(tube)에 모으고 2200 rpm에서 5 분간 원심분리하는 방법이다.First, for separation method 1, put 1 ml of dissection media in a 35 mm cell culture dish, add about 50 hair bulbs, chop them with precision scissors, and then place them in a tube. Collect and centrifuge at 2200 rpm for 5 minutes.
다음으로, 분리 방법 2는 모구 약 50개가 들어있는 35 mm 세포배양접시(cell culture dish)에 0.025% Collagenase type I 시약을 넣은 후 37 ℃, 진탕배양기(shaking incubator)에서 2시간 30분간 배양하고 튜브(tube)에 모아 2200 rpm에서 5 분간 원심분리하는 방법이다.Next, in isolation method 2, 0.025% Collagenase type I reagent was added to a 35 mm cell culture dish containing about 50 hair bulbs, cultured at 37°C for 2 hours and 30 minutes in a shaking incubator, and cultured in a shaking incubator for 2 hours and 30 minutes. This method involves collecting them in a tube and centrifuging them at 2200 rpm for 5 minutes.
상기 분리 방법 1과 2의 결과를 비교하기 위하여, 각각의 펠릿(Pellet)을 탭핑(tapping)하고 하기 표 1의 조성을 가지는 Attachment media 2 ml로 피펫팅(pipetting)을 충분히 한 후 35 mm 세포배양접시(cell culture dish)에 시딩(seeding)하고, 37℃, 5% CO2 대량증식기에서 3일 간격으로 배지를 교환해 주면서 배양접시가 세포로 가득 찰 때까지 증식시켰다. In order to compare the results of separation methods 1 and 2, each pellet was tapped and sufficiently pipetted with 2 ml of attachment media having the composition shown in Table 1 below, then placed in a 35 mm cell culture dish. They were seeded in a cell culture dish and grown in a mass propagator at 37°C and 5% CO 2 while changing the medium every 3 days until the culture dish was filled with cells.
(부착 단계)Attachment Media
(Attachment step)
상기 비교실험 결과, 0.025% Collagenase type I 시약을 넣은 분리방법 2와 비교하여, 모구 자체에 다른 처리를 하지 않고 초핑(chopping)만 진행한 분리방법 1에서 세포의 크기가 더 작고 일정하며 세포수득률도 높게 나오는 것을 확인할 수 있었다(도 1).As a result of the above comparative experiment, compared to separation method 2 using 0.025% Collagenase type I reagent, in separation method 1, in which only chopping was performed without any other treatment on the hair bulb itself, the cell size was smaller and more consistent, and the cell yield was also higher. It was confirmed that it was high (Figure 1).
실시예 3. 계대배양 단계Example 3. Subculture step
Passage 0 에서 Passage 1 로 계대배양하는 단계는 다음과 같이 실시하였다. 먼저, 35 mm 세포배양접시(cell culture dish)에서 수집된 세포수에 따라 계대배양 할 배양접시를 결정한 후, 35 mm 세포배양접시(cell culture dish)에 들어있던 배지를 버리고, PBS로 1회 세척하였다. 다음으로, 0.25% Trypsin/EDTA을 처리하고 37℃, 5% CO2 대량증식기에서 5분간 배양하였다. 이 후, 배양을 위해 1% FBS가 들어있는 MEM alpha 배지를 넣고 50ml 원심관(centrifuge tube)에 모은 후 2200 rpm에서 5 분간 원심분리 후, 상층액은 버리고 아래에 가라앉은 펠릿(pellet)을 충분히 탭핑(tapping) 한 후 표 2에 나타낸 적당량의 Expansion Media 1 또는 2를 넣고 세포수를 확인하였다.The subculture step from Passage 0 to Passage 1 was performed as follows. First, determine the culture dish to be subcultured according to the number of cells collected in the 35 mm cell culture dish, then discard the medium in the 35 mm cell culture dish and wash once with PBS. did. Next, it was treated with 0.25% Trypsin/EDTA and incubated for 5 minutes in a mass propagator at 37°C and 5% CO 2 . Afterwards, add MEM alpha medium containing 1% FBS for culture, collect in a 50ml centrifuge tube, and centrifuge at 2200 rpm for 5 minutes. Discard the supernatant and thoroughly shake off the pellet that settled at the bottom. After tapping, an appropriate amount of Expansion Media 1 or 2 shown in Table 2 was added and the number of cells was checked.
(대량증식 단계)Expansion Media 1
(Mass proliferation stage)
(대량증식 단계)Expansion Media 2
(Mass proliferation stage)
계수된 세포수에 따라 1,500개/cm2가 되도록 다음 단계의 배양접시에 시딩(seeding) 한 후, 37℃, 5% CO2 대량증식기에서 3일 간격으로 배지를 교환해 주면서 배양접시가 세포로 가득 찰 때까지 증식시켰다. Depending on the number of cells counted, seed the culture dish in the next step to reach 1,500 cells/cm 2 and then change the medium every 3 days in a mass propagator at 37°C and 5% CO 2 until the culture dish is transformed into cells. It was multiplied until full.
이 후, passage 1 내지 passage 4 로 계대배양하는 단계는 상기와 동일한 순서로 이루어지며, 계수되는 세포수에 따라 배양접시의 크기를 맞추어 passage 4까지 계대배양하였고, 중간 passage 단계에서 동결하였다가 해동할 경우에는 3,000개/cm2가 되도록 배양접시에 시딩(seeding)하였다.After this, the steps of subculturing from passage 1 to passage 4 are performed in the same order as above, and subculture was performed until passage 4 by adjusting the size of the culture dish according to the number of cells to be counted, and frozen and thawed at the intermediate passage stage. In this case, seeds were seeded in a culture dish to reach 3,000 cells/cm 2 .
실시예 4. 모유두세포 배양액 제조Example 4. Preparation of dermal papilla cell culture medium
passage 4 단계의 세포가 배양접시 바닥에 90%이상 증식한 상태에서 Expansion media를 완전히 제거하고 충분한 양의 PBS로 3회 세척하였다. 세척된 배양접시에 MEM alpha phenol red free 배지(무혈청, 무항생제 상태의 배지 사용)를 배양접시의 용량에 따라 적정량 넣고 3일, 6일에 각각의 배양된 배지를 수집하여 합친 뒤 모유두세포 배양액으로 사용하였다. When the cells at passage 4 had grown to more than 90% on the bottom of the culture dish, the expansion media was completely removed and washed three times with a sufficient amount of PBS. Add an appropriate amount of MEM alpha phenol red free medium (serum-free, antibiotic-free medium) to the washed culture dish according to the volume of the culture dish. Collect and combine each cultured medium on the 3rd and 6th days, and then add the dermal papilla cell culture fluid. It was used as.
실시예 5. 모유두세포 배양액이 함유된 탈모샴푸 제조Example 5. Preparation of hair loss shampoo containing hair papilla cell culture medium
자가배양액을 사용한 개인맞춤형 탈모샴푸를 제조함에 있어서, 샴푸에 함유되는 원료들의 함량은 아래 표 3과 같다. In manufacturing personalized hair loss shampoo using autologous culture medium, the content of raw materials contained in the shampoo is shown in Table 3 below.
실시예 6. 모유두세포 배양액 조성비에 따른 효과 확인Example 6. Confirmation of effect according to composition ratio of dermal papilla cell culture medium
실시예 6-1. 스크래치 에세이(Scratch Assay)Example 6-1. Scratch Assay
먼저 6 well plate에 면적당 2000/cm2 세포(cell)를 시딩(seeding) 하고 FBS 10%가 들어간 배지 2㎖를 분주한 후, 37℃, 5% CO2 조건에서 6일 동안 배양하였다. 6일 후 웰(well) 중앙에 자를 대고 팁(tip)을 사용하여 일정한 힘을 주어 스크래치(scratch)를 만든 후, 배지를 모두 석션(suction)하고 기본배지(basal media, 2㎖)로 1회 세척 후 한번 더 석션(suction)하였다. 그 후 각 웰(well)마다 조건별로 제조한 배지(2㎖)를 분주한 후 0시간~15시간 동안 스크래치(scratch)된 곳에서 세포가 성장하는 것을 관찰하였고, 그 결과를 도 2에 나타내었다. First, 2000/cm 2 cells per area were seeded in a 6-well plate, 2 ml of medium containing 10% FBS was dispensed, and the cells were cultured at 37°C and 5% CO 2 for 6 days. After 6 days, place a ruler in the center of the well and apply a certain amount of force using a tip to make a scratch. Then, suction all the medium and refill with basic media (2 ml) once. After washing, suction was performed once more. After that, the medium (2 ml) prepared according to the conditions was dispensed into each well, and the growth of cells in the scratched area was observed for 0 to 15 hours. The results are shown in Figure 2. .
도 2에 따르면, DPC-CM(Dermal Papilla Cell Conditioned Media) 관찰 결과 Blank인 DMEM H/G only 배지 환경에서는 15시간이 지나더라도 0 시간과 거의 차이가 없음을 알 수 있었고, 대조군(control group)인 10% FBS를 포함한 DMEM H/G 배지 환경에서는 Blank에 비해서는 조금 더 세포가 성장된 것을 관찰할 수 있었다. 0.1% DPC-CM 처리군에서는 Blank와 유사한 결과로 세포의 성장 거의 없는 것으로 관찰되었으며 1, 10, 30 % DPC-CM 처리군에서는 세포의 성장이 관찰되었으며 특히 1% DPC-CM 처리군에서 세포가 가장 잘 자라난 것을 확인할 수 있었다. 10% DPC-CM 처리군 및 그 이상의 처리군에서부터는 세포의 성장이 거의 비슷한 것으로 관찰되어 탈모조성물에 사용될 DPC-CM의 처리 농도는 1%가 적당한 것으로 확인되었다. According to Figure 2, as a result of observing DPC-CM (Dermal Papilla Cell Conditioned Media), it was found that there was almost no difference from 0 hours even after 15 hours in the blank DMEM H/G only medium environment, and the control group (control group) In the DMEM H/G medium environment containing 10% FBS, it was observed that the cells grew slightly more than in the blank. In the 0.1% DPC-CM treatment group, almost no cell growth was observed, similar to Blank, and in the 1, 10, and 30% DPC-CM treatment groups, cell growth was observed, especially in the 1% DPC-CM treatment group. It was confirmed that it grew best. Cell growth was observed to be almost similar in the 10% DPC-CM treatment group and the higher treatment group, and it was confirmed that 1% DPC-CM treatment concentration to be used in the hair loss composition was appropriate.
실시예 6-2. Cell Proliferation AssayExample 6-2. Cell Proliferation Assay
먼저 24 well plate 에 면적당 1000/cm2 세포(cell)를 시딩(seeding)하고 FBS 10%가 들어간 배지 2㎖를 분주한 후, 37℃, 5% CO2 조건에서 24시간 동안 배양하였다. 24시간 후 배지를 모두 석션(suction)한 후 조건별로 제조한 배지(2㎖)를 분주하고, 3일 후 조건별로 제조한 배지를 석션(suction)하고 10% CCK-8 solution이 들어간 FBS 10% media(1㎖)로 교체해 주었다. 90분 후 96 well plate에 조건별로 100ul씩 분주하고 450nm로 흡광도를 측정하여 도 3에 나타내었다. First, 1000/cm 2 cells per area were seeded in a 24 well plate, 2 ml of medium containing 10% FBS was dispensed, and the cells were cultured at 37°C and 5% CO 2 for 24 hours. After 24 hours, all the medium was suctioned and the medium prepared for each condition (2 ml) was dispensed. After 3 days, the medium prepared for each condition was suctioned and 10% FBS containing 10% CCK-8 solution was added. It was replaced with media (1 ml). After 90 minutes, 100ul of each condition was dispensed into a 96 well plate, and the absorbance was measured at 450nm and shown in Figure 3.
도 3에 따르면, CCK-8 (=Cell Counting Kit - 8)을 이용하여 세포의 증식을 확인한 결과 스크래치 에세이(Scratch assay) 결과와 유사하게 1% DPC-CM 처리군에서 세포의 증식이 가장 높은 것으로 확인되었다. 구체적으로, Blank, 대조군(Control group), 0.1, 0.5% DPC-CM 처리군에서는 증식이 거의 일어나지 않았으며, 특히 1, 2, 4, 6, 8, 10, 30, 50, 100% DPC-CM 처리군까지 확인한 결과 1% DPC-CM 처리군에서 세포의 증식이 가장 활발하고, DPC-CM의 농도가 높아짐에 따라 비례적으로 증식이 늘어나지는 않고, 오히려 감소되는 결과를 확인할 수 있었다. According to Figure 3, as a result of confirming cell proliferation using CCK-8 (=Cell Counting Kit - 8), cell proliferation was highest in the 1% DPC-CM treatment group, similar to the scratch assay results. Confirmed. Specifically, almost no proliferation occurred in the Blank, Control group, and 0.1 and 0.5% DPC-CM treatment groups, especially 1, 2, 4, 6, 8, 10, 30, 50, and 100% DPC-CM. As a result of checking the treatment group, it was confirmed that cell proliferation was most active in the 1% DPC-CM treatment group, and that as the concentration of DPC-CM increased, proliferation did not increase proportionally, but rather decreased.
실시예 6-3. ELISA AssayExample 6-3. ELISA Assay
먼저 실험 하루 전 96 well plate에 포획항체(Capture Antibody, CA)를 100ul씩 분주하고, CA가 코팅된 96 well plate를 실링하고 상온에서 밤샘배양(overnight) 한 후, 96 well plate를 워시버퍼(wash buffer)로 세척하였다. 그 후 96 well plate에 시약희석제(Reagent Diluent, RD) 300ul 로 1시간 동안 상온에서 Blocking하고, 1시간 후 96 well plate를 워시버퍼(wash buffer)로 세척하였다. 다음으로, Standard를 연속희석법(serial dilution)을 통하여 고농도부터 저농도로 100ul/well duplication해주고 가장 아래 웰(well)에 시약희석제(Reagent Diluent, RD)를 분주하였으며, 나머지 well에도 100ul씩 duplication하여 샘플(sample)을 분주하고 실링하여 2시간 동안 상온에서 배양하였고, 2시간 후 96 well plate를 워시버퍼(wash buffer)로 세척하고, 그 후 96 well plate에 검출항체(Detection Antibody, DA)를 100ul씩 분주하고 실링하여 2시간 동안 상온에서 인큐베이션 한 다음, 2시간 후 96 well plate을 워시버퍼(wash buffer)로 세척하였다. 그 후 Streptavidin-HRP를 100ul/well 분주하고 햇빛이 들지않는 곳에서 20분 동안 배양하고, 20분 후 96 well plate를 워시버퍼(wash buffer)로 세척하였으며, 세척 후 Substrate Solution을 100ul/well 분주하고 햇빛이 들지않는 곳에서 에서 약15분 동안 발색을 확인하였다. Standard와 sample의 발색이 확인되면 50ul/well의 Stop solution을 분주하고, 분주한 즉시 450nm으로 흡광도를 측정하여 도 4에 나타내었다. First, a day before the experiment, 100 ul of capture antibody (CA) was dispensed into each 96 well plate, the CA-coated 96 well plate was sealed and cultured overnight at room temperature, and then the 96 well plate was washed with wash buffer. Washed with buffer). Afterwards, the 96 well plate was blocked with 300ul of Reagent Diluent (RD) at room temperature for 1 hour, and after 1 hour, the 96 well plate was washed with wash buffer. Next, 100ul/well of the standard was duplicated from high concentration to low concentration through serial dilution, and reagent diluent (RD) was dispensed into the bottom well, and 100ul of each well was duplicated into the remaining wells to obtain the sample ( sample) was dispensed, sealed, and incubated at room temperature for 2 hours. After 2 hours, the 96 well plate was washed with wash buffer, and then 100 ul of detection antibody (DA) was dispensed into each 96 well plate. and sealed and incubated at room temperature for 2 hours. After 2 hours, the 96 well plate was washed with wash buffer. After that, 100ul/well of Streptavidin-HRP was dispensed and incubated for 20 minutes in a place without sunlight. After 20 minutes, the 96 well plate was washed with wash buffer. After washing, 100ul/well of Substrate Solution was dispensed. Color development was confirmed for about 15 minutes in a place out of sunlight. When the color development of the standard and sample was confirmed, 50ul/well of Stop solution was dispensed, and the absorbance was measured at 450nm immediately after dispensing, and is shown in Figure 4.
도 4에 따르면, DPC-CM을 이용하여 함유된 성장인자(Growth Factor)의 함량을 측정 한 결과 모낭조직 인근 혈관조성을 촉진하는 Human VEGF, 상피조직의 증식과 분화를 조절하여 모낭의 세포 증식을 촉진시켜 주는 Human KGF, 모유듀세포에 의해 분비되는 인자로 상피 소낭 세포의 증식을 촉진시켜 주는 Human HGF, 초기 모발의 성장을 유도 및 성장 속도를 증가시켜 주는 Human FGF, 모유두세포의 증식 및 spheroid 형성을 촉진시켜주는 Human Fibronectin 및 모발 섬유질의 구성요소인 Human Collagen 등이 분비되는 것을 확인할 수 있었다.According to Figure 4, as a result of measuring the content of growth factors using DPC-CM, Human VEGF promotes the formation of blood vessels near hair follicle tissue, and promotes cell proliferation of hair follicles by regulating proliferation and differentiation of epithelial tissue. Human KGF, a factor secreted by dermal papilla cells that promotes the proliferation of epithelial follicle cells, Human FGF, which induces early hair growth and increases the growth rate, promotes the proliferation of dermal papilla cells and spheroid formation. It was confirmed that Human Fibronectin, which promotes hair growth, and Human Collagen, a component of hair fiber, were secreted.
Claims (6)
상기 조성물은 자소엽 추출물 20 중량%, LES(Disodium Laureth Sulfosuccinate) 18 중량%, 코코베타인 14 중량%, 올리브 계면활성제 14 중량%, 글루카메이트 3.2 중량%, 모유두세포 배양액 1 중량%, 유로 나프리 0.6 중량%, 페퍼민트 정유 추출물 0.4 중량%, 로즈마리 정유 추출물 0.4 중량%, 폴리쿼터 0.4 중량% 및 정제수를 포함하는 것을 특징으로 하는 모유두세포배양액을 함유한 탈모개선용 조성물.A composition for improving hair loss containing dermal papilla cell culture medium,
The composition contains 20% by weight of perilla leaf extract, 18% by weight of LES (Disodium Laureth Sulfosuccinate), 14% by weight of coco betaine, 14% by weight of olive surfactant, 3.2% by weight of glucarate, 1% by weight of dermal papilla cell culture medium, and Eurona A composition for improving hair loss containing dermal papilla cell culture fluid, comprising 0.6% by weight of free, 0.4% by weight of peppermint essential oil extract, 0.4% by weight of rosemary essential oil extract, 0.4% by weight of polyquat, and purified water.
The composition according to claim 1, 4 or 5, wherein the composition is a shampoo, rinse, conditioner, tonic, essence, serum, treatment, lotion, wax, gel, spray, mousse, mist, or A composition for improving hair loss containing papilla cell culture medium, characterized in that it is formulated as a cream.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210109018A KR102663430B1 (en) | 2021-08-18 | 2021-08-18 | Composition for improving hair loss containing personalized dermal papilla cell culture medium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210109018A KR102663430B1 (en) | 2021-08-18 | 2021-08-18 | Composition for improving hair loss containing personalized dermal papilla cell culture medium |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20230026871A KR20230026871A (en) | 2023-02-27 |
KR102663430B1 true KR102663430B1 (en) | 2024-05-17 |
Family
ID=85329559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210109018A KR102663430B1 (en) | 2021-08-18 | 2021-08-18 | Composition for improving hair loss containing personalized dermal papilla cell culture medium |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102663430B1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101793899B1 (en) * | 2015-08-12 | 2017-11-06 | (주)프로스테믹스 | Mixed culture of adult stem cell and differentiated cell and uses thereof |
KR101743197B1 (en) * | 2015-10-30 | 2017-06-02 | 김인숙 | The manufacturing method of shampoo composition for caring scalp and promoting hair growth, and shampoo composition thereof |
KR20170132460A (en) * | 2016-05-24 | 2017-12-04 | 주식회사 디에프아이 | Scalp improved cosmetic composition comprising a stem cell culture |
KR102138241B1 (en) * | 2018-02-27 | 2020-07-28 | 주식회사 스템모어 | Composition for the preventing loss of hair and promoting growth of hair comprising rotenone as an active ingredient |
KR20200025210A (en) * | 2018-08-29 | 2020-03-10 | 주식회사 스템모어 | Composition for culturing dermal papilla cells and the method for culturing dermal papilla cells using the same |
KR102156040B1 (en) * | 2018-11-28 | 2020-09-16 | 박신성 | Natural functional shampoo for hair and scalp improvement and manufacturing method thereof |
KR102218727B1 (en) | 2020-06-17 | 2021-02-23 | 한모바이오 주식회사 | Method for isolating and mass proliferation dermal papilla cells derived from scalp tissue |
KR102254911B1 (en) | 2020-08-12 | 2021-05-24 | 한모바이오 주식회사 | Method for transplanting dermal papilla cells through perforation |
-
2021
- 2021-08-18 KR KR1020210109018A patent/KR102663430B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
비특허문헌 1 |
Also Published As
Publication number | Publication date |
---|---|
KR20230026871A (en) | 2023-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210220256A1 (en) | Hair growth promoting capacity of conditioned media of stimulated stem cells and use thereof | |
CN105246494B (en) | Composition comprising extract of neural stem cell for stimulating hair growth or preventing hair loss and method for producing the same | |
US20140295555A1 (en) | Method of culturing cells | |
EP1999250B1 (en) | Method of cultivation of human mesenchymal stem cells, particularly for the treatment of non-healing fractures, and bioreactor for carrying out this cultivation method | |
CN106659741B (en) | Hair growth promoting function of small-sized stem cells and use thereof | |
WO2020130800A1 (en) | Stem cell conditioned media | |
EP4342981A1 (en) | Novel method for isolating and culturing dermal papilla cells | |
US20230257702A1 (en) | Method for isolating and mass proliferating dermal papilla cells derived from scalp tissue | |
KR102663430B1 (en) | Composition for improving hair loss containing personalized dermal papilla cell culture medium | |
KR20220063839A (en) | Mesenchymal stem cell culture media for promoting wound healing or skin regeneration, and preventing alopecia or activating hair growth and a method for preparing the same | |
KR101026070B1 (en) | Process for culturing epidermal skin stem cells and composition for wrinkle-caring or promoting hair growth comprising the epidermal skin stem cells obtained by the process | |
Ozturk et al. | The effect of stromal vascular fraction for patients with androgenetic alopecia | |
KR20200011991A (en) | Hair Care Composition Containing Extracellular Metabolite Preparation of Bacillus Coagulum | |
KR102254911B1 (en) | Method for transplanting dermal papilla cells through perforation | |
JPH10226628A (en) | Hair papilla-activating agent | |
KR102124272B1 (en) | Composition for enhancing the action for hair growth of adipose stem cell comprising HB-EGF as an active ingredient | |
CN108823158B (en) | Application of ligustrazine and specnuezhenide in promoting proliferation of mesenchymal stem cells cultured in vitro and inhibiting replicative senescence | |
KR19990023734A (en) | Beauty composition | |
KR20230149166A (en) | Method for isolating and culturing immune-compatible dermal papilla cells for allograft and uses thereof | |
KR20240096413A (en) | cosmetic composition containing polygammaglutamic acid and adipose tissue-derived stem cell exosomes | |
JP7214191B2 (en) | Stem cell undifferentiated state maintenance agent and growth promoter | |
CN109833339B (en) | Composition for promoting proliferation of stem cells and tissue regeneration of skin injury wound | |
JP7089267B2 (en) | Hair follicle stem cell undifferentiated state maintainer | |
KR20220116805A (en) | Method for transplanting dermal papilla cells through perforation | |
WO2017019713A1 (en) | Mulateiro-derived compositions and use thereof for preventing hair loss and promoting hair growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |